down arrow

Annovis Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03615A1088
USD
3.65
-0.02 (-0.54%)

Dec 19

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Pyxis Oncology, Inc.
CytomX Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Chimerix, Inc.
aTyr Pharma, Inc.
DiaMedica Therapeutics, Inc.
GlycoMimetics, Inc.
Achieve Life Sciences, Inc.
Atossa Therapeutics, Inc.
Relmada Therapeutics, Inc.
Annovis Bio, Inc.
Why is Annovis Bio, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Annovis Bio, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Annovis Bio, Inc.
-17.05%
-0.39
106.61%
S&P 500
16.49%
0.70
20.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-229.09%
EBIT to Interest (avg)
-22.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.94%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.60
EV to EBIT
-1.60
EV to EBITDA
-1.60
EV to Capital Employed
22.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1384.59%
ROE (Latest)
-110.36%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -24.7 MM

NET PROFIT(HY)

Higher at USD -12.18 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Here's what is working for Annovis Bio, Inc.
Net Profit
Higher at USD -12.18 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Cash Flow
Highest at USD -24.7 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."